These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32159286)

  • 41. New therapies using nonfactor products for patients with hemophilia and inhibitors.
    Nogami K; Shima M
    Blood; 2019 Jan; 133(5):399-406. PubMed ID: 30559263
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
    Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.
    Stagaard R; Flick MJ; Bojko B; Goryński K; Goryńska PZ; Ley CD; Olsen LH; Knudsen T
    J Thromb Haemost; 2018 Jul; 16(7):1369-1382. PubMed ID: 29758126
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of antithrombin by protein SV-IV normalizes the coagulation of hemophilic blood.
    Di Micco B; Caen J; Colonna G; Macalello MA; Marchese M; Stiuso P; Di Micco P; Morelli F; Metafora S
    Eur J Pharmacol; 2000 Mar; 391(1-2):1-9. PubMed ID: 10720629
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.
    Batsuli G; Deng W; Healey JF; Parker ET; Baldwin WH; Cox C; Nguyen B; Kahle J; Königs C; Li R; Lollar P; Meeks SL
    Blood; 2016 Oct; 128(16):2055-2067. PubMed ID: 27381905
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.
    Pasi KJ; Lissitchkov T; Mamonov V; Mant T; Timofeeva M; Bagot C; Chowdary P; Georgiev P; Gercheva-Kyuchukova L; Madigan K; Van Nguyen H; Yu Q; Mei B; Benson CC; Ragni MV
    J Thromb Haemost; 2021 Jun; 19(6):1436-1446. PubMed ID: 33587824
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of heparins on thrombin generation in hemophilic plasma supplemented with FVIII, FVIIa, or FEIBA.
    Parmar N; Berry LR; Paredes N; Chan AK
    Clin Lab; 2005; 51(3-4):157-66. PubMed ID: 15819171
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene-based continuous expression of FVIIa for the treatment of hemophilia.
    Margaritis P
    Front Biosci (Schol Ed); 2012 Jan; 4(1):287-99. PubMed ID: 22202061
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice.
    Bolliger D; Szlam F; Suzuki N; Matsushita T; Tanaka KA
    Thromb Haemost; 2010 Jun; 103(6):1233-8. PubMed ID: 20352163
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.
    Jiang H; Lillicrap D; Patarroyo-White S; Liu T; Qian X; Scallan CD; Powell S; Keller T; McMurray M; Labelle A; Nagy D; Vargas JA; Zhou S; Couto LB; Pierce GF
    Blood; 2006 Jul; 108(1):107-15. PubMed ID: 16522813
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selective inhibition of activated protein C anticoagulant activity protects against hemophilic arthropathy in mice.
    Magisetty J; Kondreddy V; Keshava S; Das K; Esmon CT; Pendurthi UR; Rao LVM
    Blood; 2022 May; 139(18):2830-2841. PubMed ID: 35143636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice.
    Bunting S; Zhang L; Xie L; Bullens S; Mahimkar R; Fong S; Sandza K; Harmon D; Yates B; Handyside B; Sihn CR; Galicia N; Tsuruda L; O'Neill CA; Bagri A; Colosi P; Long S; Vehar G; Carter B
    Mol Ther; 2018 Feb; 26(2):496-509. PubMed ID: 29292164
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.
    Doshi BS; Gangadharan B; Doering CB; Meeks SL
    PLoS One; 2012; 7(10):e48172. PubMed ID: 23144741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
    Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
    J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.
    Quade-Lyssy P; Abriss D; Milanov P; Ungerer C; Königs C; Seifried E; Schüttrumpf J
    J Thromb Haemost; 2014 Nov; 12(11):1861-73. PubMed ID: 25224783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.
    Bhat V; von Drygalski A; Gale AJ; Griffin JH; Mosnier LO
    Thromb Haemost; 2016 Mar; 115(3):551-61. PubMed ID: 26466980
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A.
    Muczynski V; Verhenne S; Casari C; Chérel G; Panicot-Dubois L; Gueguen P; Trossaert M; Dubois C; Lenting PJ; Denis CV; Christophe OD
    Thromb Haemost; 2019 Dec; 119(12):1981-1993. PubMed ID: 31639831
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs.
    Gallo-Penn AM; Shirley PS; Andrews JL; Tinlin S; Webster S; Cameron C; Hough C; Notley C; Lillicrap D; Kaleko M; Connelly S
    Blood; 2001 Jan; 97(1):107-13. PubMed ID: 11133749
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists.
    de Koning MLY; Fischer K; de Laat B; Huisman A; Ninivaggi M; Schutgens REG
    J Thromb Haemost; 2017 May; 15(5):868-875. PubMed ID: 28296129
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Blood coagulation in hemophilia A and hemophilia C.
    Cawthern KM; van 't Veer C; Lock JB; DiLorenzo ME; Branda RF; Mann KG
    Blood; 1998 Jun; 91(12):4581-92. PubMed ID: 9616154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.